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ABSTRACT
Papillary proliferation of the endometrium is an unusual lesion that is composed 
of papillae with fibrovascular stromal cores covered with benign-appearing glandular 
epithelium. We studied the clinicopathological and immunohistochemical features of 
four cases of endometrial papillary proliferations. All patients were postmenopausal. 
Two lesions were incidental findings in hysterectomy specimens, and two lesions were 
detected in endometrial curettage specimens. Based on the degree of architectural 
complexity and extent of proliferation, we classified papillary proliferations 
histopathologically into “simple” or “complex” growth patterns. Three cases were 
classified as simple papillary proliferation, and one case was classified as complex 
papillary proliferation. Simple papillary proliferations were characterized by slender 
papillae with delicate stromal cores. In contrast, complex papillary proliferations 
had intracystic papillary projections and cellular clusters with frequent branching 
and occasional cytological atypia. All cases showed coexistent metaplastic epithelial 
changes, including mucinous metaplasia, eosinophilic cell change, and ciliated cell 
metaplasia. One patient with simple papillary proliferations had coexistent well-
differentiated endometrioid carcinoma. One patient had subsequent hyperplasia 
without atypia, and another patient had subsequent atypical hyperplasia/endometrioid 
intraepithelial neoplasia; both patients underwent total hysterectomy within four 
months. Our observations are consistent with previous data demonstrating that 
endometrial papillary proliferations coexist with or develop into atypical hyperplasia/
endometrioid intraepithelial neoplasia or endometrioid carcinoma. It is very important 
for pathologists to discriminate papillary proliferations from neoplastic lesions 
(including atypical hyperplasia/endometrioid intraepithelial neoplasia and well-
differentiated endometrioid carcinoma) and benign mimickers (including papillary 
syncytial metaplasia).
INTRODUCTION
Papillary lesions of the endometrium are 
characteristically observed in cases of malignant 
tumors such as endometrioid and serous carcinomas. 
Slender papillae are not commonly found in the normal 
endometrium or benign endometrial lesions. However, 
if they are thin, delicate fibrovascular stromal cores that 
are localized to the endometrial surface and do not show 
malignant nuclear features—such papillae are considered 
“papillary proliferation of the endometrium” or a “benign 
papillary change” [1, 2]. In contrast, proliferative papillae 
with significant nuclear atypia, remarkable architectural 
complexity, or stromal invasion should be diagnosed as 
atypical hyperplasia/endometrioid intraepithelial neoplasia 
or well-differentiated endometrioid carcinoma.
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Recently, we recognized a few cases of endometrial 
papillary proliferation in postmenopausal women. 
Based on the literature, papillary proliferation of the 
endometrium can be categorized histopathologically into 
two groups: simple and complex papillary proliferation 
[1, 2]. The former exhibits thin papillae with delicate 
fibrovascular stromal cores. In contrast, the latter has 
intracystic papillary invaginations and floating cellular 
clusters with frequent branching. Simple papillary 
proliferation tends to have favorable outcomes, while there 
is a high probability that complex papillary proliferation 
coexists with or will develop into atypical hyperplasia/
endometrioid intraepithelial carcinoma or endometrioid 
carcinoma. In 2014, as the World Health Organization 
Classification of Tumours of Female Reproductive 
Organs was being amended, papillary proliferation was 
added as a type of metaplastic epithelial change that 
occurs in the endometrium [3]. However, most studies 
of endometrial papillary proliferation have been case 
reports, which have been published only occasionally 
and have focused on its differential diagnosis from well-
differentiated endometrioid carcinoma. To date, only two 
studies have investigating the clinicopathological features 
of endometrial papillary proliferation: a study by Lehman 
and Hart [2], in which nine cases were reported, and a 
study by Ip and colleagues [1], in which 59 cases were 
reported. The small number of studies that has been 
published regarding papillary proliferation suggests that 
it is quite a rare entity. In the present study, we report our 
experience with a series of four patients who had simple or 
complex papillary proliferations of the endometrium. We 
thoroughly demonstrate the clinical and histopathological 
features and immunophenotype of endometrial papillary 
proliferations.
RESULTS
Summary of clinicopathological features
The ages of the patients ranged from 57 to 70 years 
(mean, 64 years). All patients were postmenopausal. 
Three patients (cases 2, 3, and 4) presented with abnormal 
vaginal bleeding. A thickened endometrium was 
discovered on ultrasonographic scans in three patients 
(cases 2, 3, and 4). One patient (case 3) was receiving 
estrogen replacement therapy. No patient was receiving 
exogenous progestin, tamoxifen, clomiphene citrate, 
danazol, or gonadotropin-releasing hormone agonist. 
The histopathological diagnosis of endometrial papillary 
proliferation was made based on curettage specimens in 
two cases (cases 2 and 3) and hysterectomy specimens 
in two cases (cases 1 and 4). One of the hysterectomies 
(case 1) was performed for cervical high-grade squamous 
intraepithelial lesion. The other hysterectomy was 
performed because of endometrial thickening in a patient 
who had a history of endometrial hyperplasia (case 4). 
Three cases (cases 1, 3, and 4) were classified as simple 
papillary proliferation, and one case was classified as 
complex papillary proliferation (case 2). In case 2, an 
endometrial polyp was present, and was extensively 
involved by the complex papillary proliferation. With 
the exception of this case, the amount of endometrium 
involved by the papillary change was small (less than 
10% of the entire endometrial volume) in all cases. All 
cases displayed coexistent metaplastic epithelial changes; 
the most common type was mucinous metaplasia (cases 
1, 2, and 4). Coexistent well-differentiated (International 
Federation of Gynecology and Obstetrics [FIGO] grade 
1) endometrioid carcinoma with a background of atypical 
hyperplasia/endometrioid intraepithelial neoplasia was 
found in one case (case 4). One patients had subsequent 
hyperplasia without atypia (case 3), and another patient 
had subsequent atypical hyperplasia/endometrioid 
intraepithelial neoplasia (case 2); both of these patients 
underwent total hysterectomy within four months.
Case presentation
Case 1: A 57-year-old postmenopausal woman was 
referred from an outside hospital after a cervical punch 
biopsy revealed a high-grade squamous intraepithelial 
lesion (cervical intraepithelial neoplasia 3). On physical 
examination, she was alert, cooperative, and in no apparent 
distress. She was asymptomatic and had no significant 
history of intake of hormonal medications. She underwent 
cervical conization, followed by total laparoscopic 
hysterectomy and bilateral salpingo-oophorectomy. 
Pathological examination of the conization specimen 
confirmed a high-grade squamous intraepithelial lesion 
with endocervical glandular extension and clear resection 
margins.
Case 2: A 65-year-old postmenopausal woman 
presented with a three-day history of vaginal bleeding. She 
had no history of gynecological disease. Her last menstrual 
period was 9 years ago. She had no history of hormone 
replacement therapy. Transvaginal ultrasonography 
revealed an endometrial thickening, which measured 8 
mm at its maximum thickness. She underwent diagnostic 
hysteroscopy, which showed an irregular exophytic 
lesion with a 12 mm diameter in the fundic side of the 
endometrial cavity. A hysteroscopic polypectomy with 
diagnostic endometrial curettage was performed.
Case 3: A 64-year-old postmenopausal woman 
presented with vaginal bleeding and a persistently 
increased endometrial thickness on ultrasonography. Her 
last menstrual period was 6 years ago, and she had been 
on estrogen replacement therapy ever since. During the 
last year that she received estrogen replacement therapy, 
a routine transvaginal ultrasonography showed an 
endometrial thickness of 10 mm, but endometrial curettage 
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revealed a secretory endometrium without evidence 
of hyperplasia or malignancy. Despite being moved to 
a continuous combined preparation, her endometrial 
thickness remained at 10 mm on ultrasonography. As 
the endometrial thickness persisted, a repeat endometrial 
curettage was performed.
Case 4: A 70-year-old postmenopausal woman 
presented with vaginal spotting that had lasted 6 days. 
She had reached menopause 20 years earlier. Two years 
previously, she underwent a dilatation and curettage 
procedure at another hospital, and was reported to have 
had hyperplasia without atypia. At that time, she refused 
to undergo hysterectomy. She denied any history of 
taking hormone replacement therapy. Transvaginal 
ultrasonography revealed a thickened endometrium. The 
maximal thickness of the endometrium was measured at 
14 mm. Other investigations did not reveal any remarkable 
findings. Total laparoscopic hysterectomy with bilateral 
salpingo-oophorectomy was performed.
Histopathological findings and follow-up 
information
Case 1: On gross examination, no grossly visible 
mass was identified in the endometrium, and the cervix 
had no residual lesions. Hematoxylin and eosin-stained 
sections revealed a localized papillary arrangement of 
endometrial glandular epithelium (Figure 1A). The lesion 
was confined to the endometrium. Variably enlarged 
endometrial glands were completely embedded in the 
stroma. The papillae protruded into a cystically dilated 
endometrial glandular lumen with several floating clusters 
of epithelium (Figure 1B). The glandular lumina were 
lined by a single, uniform layer of columnar epithelial 
cells with apical cytoplasmic snouts or secretions (Figure 
1C). The epithelium covering the papillae exhibited the 
same morphologic features as the luminal epithelial lining 
(Figure 1D). The papillae had a “simple” architectural 
pattern [1, 2]. The slender papillae had relatively well-
defined fibrovascular stromal cores with rare branches 
(Figure 1E). The individual epithelial cells demonstrated 
no cytological atypia, had preserved nuclear polarity, and 
had a uniform nuclear chromatin pattern. The majority of 
these cells had oval nuclei without prominent nucleoli. A 
minority of the papillae was covered by cells with rounder 
nuclear outlines or with small nucleoli; however, these 
features were not associated with an abnormal chromatin 
pattern or nuclear membrane irregularities. Metaplastic 
epithelial changes were also identified within a few 
areas of papillary proliferation. In these areas, papillae 
were covered by uniform, mucin-containing cuboidal 
or low columnar cells with basal nuclei (mucinous 
metaplasia), or by tall, ciliated columnar cells (ciliated 
cell metaplasia). Eosinophilic cell change and papillary 
syncytial metaplasia were also present. Simple papillary 
proliferation was offered as the final diagnosis.
Case 2: Hematoxylin and eosin-stained sections 
Table 1: Clinicopathological summary of endometrial papillary proliferations
Case
Clinical feature Histopathological feature
Age MP HRT
Previous
gynecological
history
Clinical
presentation
Current
status
Type of
specimen
Pattern of
papillary
proliferation
Volume of
papillary
proliferation
Metaplastic
epithelial
change
Relation with
EM hyperplasia or 
carcinoma
1 57 Yes No Cervical HSIL No symptom NED Hysterectomy Simple <10% ofentire EM M, C, E, P No
2 65 Yes No No
Vaginal 
bleeding,
EM polyp
NED Curettage Complex 80% ofEM polyp M, E
Subsequent atypical 
hyperplasia/EIN
in hysterectomy 
specimen (after 4 
months)
3 64 Yes Yes No
Vaginal 
bleeding,
Thickened EM
NED Curettage Simple <10% ofentire EM M, C, E
Subsequent 
hyperplasia without 
atypia
in hysterectomy 
specimen (after 3 
months)
4 70 Yes No
EM 
hyperplasia
without atypia
Vaginal 
spotting,
Thickened EM
NED Hysterectomy Simple <10% ofentire EM M, E
Coexistent well-
differentiated EM 
carcinoma
in hysterectomy 
specimen
C: ciliated cell metaplasia, E: eosinophilic cell change, EIN: endometrioid intraepithelial neoplasia, EM: endometrium, HRT: 
hormone replacement therapy, HSIL: high-grade squamous intraepithelial lesion, M: mucinous metaplasia, MP: menopause, 
NED: no evidence of disease, P: papillary syncytial metaplasia.
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revealed predominantly papillary architecture (Figure 2A), 
which involved an endometrial polyp, comprised primary 
and secondary papillae, and formed intraluminal papillary 
projections (Figure 2B). The complex papillae displayed 
mucinous metaplasia and mild nuclear atypia (Figure 2C). 
In a few areas, intracystic papillary cell clusters showed 
nuclear stratification and overlapping. Some of the 
individual epithelial cells had a rounder nuclear outline, 
slight irregularity in their nuclear membranes, and a small 
nucleolus; however, these two features were never diffuse 
and never associated with an abnormal chromatin pattern 
or significant nuclear membrane irregularity (Figure 2D). 
The final diagnosis was complex papillary proliferation, 
involving approximately 80% of endometrial polyp. 
Because persistent complex papillary proliferation was 
observed in the specimen of an endometrial curettage 
that was performed four months later, total laparoscopic 
hysterectomy was performed. The hysterectomy specimen 
showed multifocal atypical hyperplasia/endometrioid 
intraepithelial neoplasia that was adjacent to the complex 
papillary proliferation. There was no evidence of invasive 
carcinoma.
Case 3: At low magnification, various sizes of 
detached clusters of epithelial cells were observed to fill 
the irregularly dilated glandular lumina (Figure 3A). Some 
papillae showed a villous appearance or had cellular tufts 
on their surfaces. However, no obvious second or third 
branching was observed. The bland-appearing epithelial 
cells covering the thin fibrovascular stromal cores did 
not exhibit nuclear pleomorphism, loss of polarity, or 
conspicuous nucleoli. The cytoplasm was eosinophilic 
(eosinophilic cell change) or granular and basophilic 
(mucinous metaplasia) in the apical region. Some 
epithelial cells had cilia protruding into the glandular 
lumen (ciliated cell metaplasia). Mucinous metaplasia 
was more prominent in the epithelial cells that composed 
the detached intraluminal floating clusters (Figure 3B). In 
the stroma, a moderate degree of chronic inflammatory 
infiltrate was observed. These histopathological features 
were consistent with simple papillary proliferation. 
No evidence of coexistent endometrial hyperplasia or 
carcinoma was identified. The patient was followed 
up for three months while she continued to receive the 
combined hormone therapy, but slight vaginal bleeding 
occurred again. Subsequent ultrasonography showed an 
endometrial thickness of 7 mm, and a diagnostic dilatation 
and curettage procedure was performed. Residual simple 
papillary proliferation was observed, as well as hyperplasia 
without atypia. Finally, total laparoscopic hysterectomy 
was performed. In the hysterectomy specimen, residual 
hyperplasia without atypia was observed, but no residual 
papillary proliferation was found. 
Case 4: The hysterectomy specimen revealed a well-
differentiated (FIGO grade 1) endometrioid carcinoma 
that invaded the superficial myometrium (FIGO stage 
IA). The largest dimension and greatest invasion depth of 
the tumor were 8 mm and 2 mm, respectively. Multifocal 
atypical hyperplasia/endometrioid intraepithelial neoplasia 
was observed around the carcinoma. In addition, a few 
microscopic areas showing papillary proliferations were 
found immediately adjacent to the carcinoma (Figure 
4A). The glandular lumina were lined by a single 
layer of bland-appearing epithelial cells (Figure 4B). 
In resemblance with the histologic features of case 1, 
the papillae had a “simple” architectural pattern. The 
histopathological features were consistent with simple 
papillary proliferation. In contrast, areas of endometrioid 
carcinoma exhibited back-to-back glandular crowding and 
severe cytologic atypia that included nuclear rounding, 
significant pleomorphism, vesicular chromatin pattern, 
and prominent nucleoli, which were morphologically 
compatible with malignancy (Figure 4C).
Immunohistochemical findings
The results of immunohistochemical staining are 
summarized in Table 2, and representative immunostaining 
photomicrographs are shown in Figure 5. p16 expression 
was negative in one case and was patchy positive in three 
cases (Figure 5A). In all cases, p53 was expressed at 
low levels localized in the nuclei of some epithelial cells 
(Figure 5B), indicating the wild-type TP53 gene. AT-rich 
interactive domain-1α (ARID1A; Figure 5C), phosphatase 
and tensin homolog (PTEN; Figure 5D), and paired box 2 
(PAX2; Figure 5E) were well preserved in all cases. The 
expression patterns of p16/p53 and PTEN/PAX2 excluded 
the possibilities of endometrial serous and endometrioid 
carcinoma, respectively. The Ki-67 labeling index was 5% 
or less in all cases (Figure 5F). Estrogen receptor (Figure 
5G) and progesterone receptor (Figure 5H) were strongly 
positive in all cases. 
DISCUSSION
Although both of the two previous studies by 
Lehman and Heart [2] and Ip and colleagues [1] classified 
papillary proliferation into a simple pattern and a complex 
pattern, the latter additionally emphasized that the two 
patterns have different biological significance. Given 
that 81% (17/21) of complex papillary proliferation cases 
are associated with concurrent or subsequent atypical 
hyperplasia/endometrioid intraepithelial neoplasia or 
endometrioid carcinoma, Ip and colleagues [1] insisted 
that complex papillary proliferation should be managed 
in the same way as is atypical hyperplasia/endometrioid 
intraepithelial neoplasia. They also noted that there 
is a high risk of coexistent or subsequent endometrial 
hyperplasia when papillary proliferation involves more 
than 50% of an endometrial polyp. In contrast with their 
observations, we found that one patient with simple 
papillary proliferation had coexistent well-differentiated 
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Figure 1: Histopathological findings of Case 1: Simple papillary proliferation, incidentally detected. A. Several cystically 
dilated glandular lumina contained papillary invaginations and floating cellular clusters. B. Grouped, dilated endometrial glands were 
embedded within the stroma. C. The epithelial cells lining the dilated glandular lumen were a single layer of columnar epithelial cells 
with frequent apical cytoplasmic snouts. D. The slender papillae had relatively well-defined fibrovascular stromal cores, and were rarely 
branched. Variable-sized, intraluminal floating clusters of epithelial cells were also seen. E. Cytologically, the majority of the epithelial cells 
had no cytologic atypia, had preserved nuclear polarity, had uniform nuclear chromatin pattern, and had no prominent nucleoli.
Figure 2: Histopathological findings of Case 2: Complex papillary proliferation, extensively involving an endometrial 
polyp. A. A scanning view of the endometrial polypectomy specimen showed a predominantly papillary growth and intraluminal papillary 
projections. An endometrial polyp was replaced by a florid papillary proliferation that involved most of the glands. B. Complexly branching 
papillary processes appeared to arise from the lining of the endometrial glandular epithelium. C. The stromal cores were covered with 
metaplastic mucinous epithelium. D. In a few areas, papillary cell clusters exhibited focal nuclear stratification, mild anisonucleosis, and 
mild nuclear atypia. However, none of them showed an abnormal chromatin pattern or significant irregularity in the nuclear membrane.
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endometrioid carcinoma, and that another patient with 
simple papillary proliferation also had subsequent atypical 
hyperplasia/endometrioid intraepithelial neoplasia. In both 
cases, simple papillary proliferation was not accompanied 
by endometrial polyp and involved less than 10% of the 
entire endometrial volume. Because we only experienced 
a small number of cases, and because only a few studies 
have been reported to date, it is currently difficult to 
reach any definitive conclusions; however, we should not 
overlook the fact that endometrial precancerous lesions 
and carcinoma may be accompanied by simple papillary 
proliferation. At least, our findings were consistent with a 
minor observation by Ip and colleagues [1] in that three 
cases of simple papillary proliferation involved less than 
50% of the endometrial polyp and were accompanied by 
atypical hyperplasia/endometrioid intraepithelial neoplasia 
and carcinoma.
In the present study, we determined the 
immunophenotype of papillary proliferation. Previously, 
the immunophenotype of papillary proliferation had 
only been described in one case report of Rekhi and 
colleagues [4]. The presence of patchy p16 expression 
and scattered, weak p53 nuclear immunoreactivity rules 
out the possibility of endometrial serous carcinoma [5]. 
Similarly, a low Ki-67 proliferation index and uniform 
estrogen receptor/progesterone receptor positivity does 
not support the diagnosis of endometrial serous carcinoma 
[6]. This result was consistent with the report of Rekhi 
and colleagues [4], who observed diffuse estrogen receptor 
expression, low Ki-67 staining, and weak, focal p53 
expression in complex papillary proliferation. In addition, 
PTEN mutation is the most common genetic abnormality 
Figure 3: Histopathological findings of Case 3: Simple papillary proliferation, showing apparent mucinous metaplasia. 
A. A cystically dilated glandular lumen contained several detached cellular clusters, some of which had cellular tufts on their surfaces. B. 
In this case, mucinous metaplastic changes were prominent. Although they were also observed in the lining of the epithelium, metaplastic 
mucinous epithelium was more noticeable in floating cellular clusters. The cytoplasm was granular and amphiphilic to basophilic, which is 
consistent with endocervical-type mucinous epithelium. The epithelial cells covering the papillae had preserved nuclear polarity, had little 
variation in nuclear size and shape, had uniform nuclear chromatin, and lacked conspicuous nucleoli.
Figure 4: Histopathological findings of Case 4: Simple papillary proliferation, closely adjacent to a well-differentiated 
endometrioid carcinoma. A. Simple papillae (blue border) abutted a well-differentiated (FIGO grade 1) endometrioid carcinoma 
(red border). B. Slender papillae with delicate stromal cores were covered by bland-appearing epithelial cells with clear to eosinophilic 
cytoplasm. Severe cytologic atypia and conspicuous nucleoli were absent. C. In contrast, endometrioid carcinoma displayed a complex 
glandular architecture with loss of intervening stroma (back-to-back glandular crowding or cribriform pattern) and severe cytologic atypia. 
The individual tumor cells exhibited nuclear rounding, pleomorphism, loss of polarity, and conspicuous nucleoli.
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Figure 5: Immunohistochemical findings of endometrial papillary proliferation. A. Patchy p16 immunoreactivity in the 
cytoplasm excluded the possibility of serous carcinoma. B. Faint to weak, focal p53 expression in a few epithelial cells indicated wile-
type TP53, excluding the possibility of serous carcinoma. C. to E. In the epithelial cells of the endometrial papillary proliferation, the 
expressions of C. ARID1A, D. PTEN, and E. PAX2 were well preserved. F. Ki-67 labelling index was not significantly increased (less than 
1%). G. and H. The epithelial cells of the endometrial papillary proliferation exhibited diffuse, strong immunoreactivity for G. estrogen 
receptor and H. progesterone receptor.
Table 2: Immunostaining results of endometrial papillary proliferations
Antibody Case 1 Case 2 Case 3 Case 4
ARID1A No loss No loss No loss No loss
ER Diffuse, strong positive Diffuse, strong positive Diffuse, strong positive Diffuse, strong positive
Ki-67 Less than 1% About 5% Less than 1% Less than 1%
p16 Patchy positive Patchy positive Negative Patchy positive
p53 Focal, weak positive Focal, weak positive Focal, weak positive Focal, weak positive
PAX2 No loss No loss No loss No loss
PR Diffuse, strong positive Focal, strong positive Diffuse, strong positive Focal, strong positive
PTEN No loss No loss No loss No loss
ARID1A: AT-rich interactive domain-1α, ER: estrogen receptor, PAX2: paired box 2, PR: progesterone receptor, PTEN: 
phosphatase and tensin homolog.
Table 3: Antibodies used for immunostaining
Antibody Source Clone Dilution
ARID1A Sigma-Aldrich Corp., St. Louis, MO, USA Polyclonal 1:200
ER Thermo Fisher Scientific Inc., Fremont, CA, USA SP1 1:100
Ki-67 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA MIB-1 1:150
p16 Ventana Medical Systems, Inc., Tucson, AZ, USA E6H4 Prediluted
p53 NovoCastra Laboratories, Ltd,, Newcastle upon Tyne, UK DO-7 1:300
PAX2 GeneTex, Inc., Irvine, CA, USA EP3251 1:1,000
PR Dako, Agilent Technologies, Inc., Carpinteria, CA, USA PgR 636 1:50
PTEN Cell Signaling Technology, Danvers, MA, USA D4.3 1:100
ARID1A: AT-rich interactive domain-1α, ER: estrogen receptor, PAX2: paired box 2, PR: progesterone receptor, PTEN: 
phosphatase and tensin homolog.
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of endometrial endometrioid carcinoma [3, 7, 8]. Lack of 
PTEN immunoreactivity indicates the presence of PTEN 
mutation. We did not observe the loss of PTEN expression 
in any case. Meanwhile, uniform PAX2 immunoreactivity 
is rarely observed in atypical hyperplasia/endometrioid 
intraepithelial neoplasia or carcinoma; lack of PAX2 
in endometrial hyperplasia suggests cytological atypia 
or architectural complexity [9]. None of the cases we 
examined showed loss of PAX2 expression. Moreover, 
loss of ARID1A expression is known to occur in 
approximately 40% of low-grade endometrioid carcinomas 
[10-12]. However, like loss of PAX2 expression, loss of 
AID1A expression was not observed in our cases. We 
investigated whether papillary proliferation exhibits an 
aberrant immunophenotype, as is observed in endometrial 
precancerous lesions and carcinomas, but we did not 
obtain any significant results. Even though our findings 
do not support the argument that papillary proliferation of 
the endometrium may be a precursor lesion of endometrial 
carcinoma, the immunophenotype of endometrial papillary 
proliferation should be investigated further in larger 
samples.
It is also important to recognize that benign 
endometrial entities may be misdiagnosed as papillary 
proliferation. In particular, one should be careful not 
to misdiagnose papillary syncytial metaplasia and 
pseudopapillary artifacts in endometrial curettage 
specimens as papillary proliferation. Papillary syncytial 
metaplasia is a form of epithelial metaplasia of the 
endometrial glands that is associated with glandular and 
stromal breakdown [5, 13-15]. It is a common reparative 
change that may be found on the surface of an endometrial 
polyp in patients with anovulatory dysfunctional bleeding, 
endometrial hyperplasia, or a history of hormone 
treatment [15]. These regenerating epithelial cells often 
possess abundant, eosinophilic cytoplasm. Generally, the 
papillae in the papillary syncytial metaplasia do not have 
prominent fibrovascular stromal cores. Instead, they are 
often associated with neutrophils, nuclear debris, and other 
changes that occur with menstruation. The metaplastic 
epithelial cells form disorganized syncytial aggregates 
[13]. In endometrial papillary proliferation, the epithelial 
cells are not aligned in an orderly manner. The small, bud-
like, floating papillae seen in papillary proliferation may 
appear similar to those observed in syncytial papillary 
change. Therefore, it can be difficult to distinguish these 
two entities. Curettage-related artifacts may produce a 
pseudopapillary pattern and may also be misdiagnosed as 
papillary proliferation. However, pseudopapillary artifacts 
created by curettage can be discriminated from papillary 
proliferations because they are limited to a single or a few 
glandular spaces accompanied by prominent, surrounding 
epithelial fragmentation.
In summary, we have described the 
clinicopathological and immunohistochemical features 
of endometrial papillary proliferation. In two cases, 
endometrial papillary proliferation was observed in 
the specimens from endometrial curettage procedures 
that had been performed to evaluate postmenopausal 
vaginal bleeding and thickened endometrium; in both 
of these cases, subsequent endometrial hyperplasia 
was observed during follow-up and hysterectomy was 
therefore performed. In another case, we observed simple 
papillary proliferation adjacent to well-differentiated 
endometrioid carcinoma. Our observations support 
the notion that endometrial papillary proliferations 
coexist with or develop into atypical hyperplasia/
endometrioid intraepithelial neoplasia or endometrioid 
carcinoma. However, the immunophenotype of the 
endometrial papillary proliferations suggests that they 
have benign natures and are not precancerous lesions. 
Further investigations are needed to confirm or disprove 
this hypothesis. It is very important for pathologists to 
discriminate papillary proliferations from neoplastic 
lesions, as well as benign mimickers.
MATERIALS AND METHODS
Case selection
The cases were selected from the computerized 
files of Severance Hospital, Yonsei University College 
of Medicine. A thorough search was performed using the 
key words “endometrium,” “papillary,” “atypical papillary 
proliferation,” “papillary growth pattern,” and “papillary 
hyperplasia” in the archival surgical pathology cases. 
During the period from January 2006 to December 2015, 
50 patients were diagnosed with benign or malignant 
papillary endometrial lesions, including serous carcinoma 
with dominant papillary growth pattern (46.0%; 23/50), 
well-differentiated endometrioid carcinoma with papillary 
growth pattern (16.0%; 8/50), papillary syncytial 
metaplasia (12.0%; 6/50), villoglandular papillary 
carcinoma (8.0%; 4/50), mixed serous and endometrioid 
carcinoma (6.0%; 3/50), carcinosarcoma (4.0%; 2/50), and 
papillary proliferation of the endometrium (8.0%; 4/50). 
Clinical and pathological information were obtained from 
the electrical medical information systems and pathology 
reports. The clinical details that were reviewed included 
the age of patient at diagnosis, presenting complaint, 
gynecological history, and subsequent curettage or 
hysterectomy results. The present study was reviewed and 
approved by the Institutional Review Board at Severance 
Hospital, Yonsei University Health System, Seoul, 
Republic of Korea (2016-0481-001).
Histopathological examination
The resected or curetted specimens were 
fixed in neutral buffered formalin and embedded in 
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paraffin blocks. Four-micrometer formalin-fixed, 
paraffin-embedded sections were cut from the blocks, 
stained with hematoxylin and eosin, and prepared for 
immunohistochemical staining. The slides were examined 
under routine light microscopy. The histopathological 
features that were assessed included architectural 
complexity, extent of papillae, any coexistent metaplastic 
epithelial changes, any coexistent hyperplasia or 
carcinoma, and status of the background endometrium. 
Endometrial hyperplasia was classified according to the 
World Health Organization as hyperplasia without atypia 
or atypical hyperplasia/endometrioid intraepithelial 
neoplasia [3]. Any subsequent endometrial curettage or 
hysterectomy specimens were obtained and reviewed 
histopathologically.
Immunohistochemistry
Four-micrometer formalin-fixed, paraffin-embedded 
tissue sections were deparaffinized and rehydrated with 
a xylene and alcohol solution. Immunohistochemical 
staining was performed using the Ventana Benchmark XT 
automated staining system (Ventana Medical Systems, 
Inc., Tucson, AZ, USA) or Dako Omnis (Dako, Agilent 
Technologies, Inc., Carpinteria, CA, USA) according 
to the manufacturer’s instructions. Antigen retrieval 
was performed using Cell Conditioning Solution (CC1; 
Ventana Medical Systems, Inc.) or EnVision FLEX Target 
Retrieval Solution, High pH (Dako, Agilent Technologies, 
Inc.). The tissue sections were subsequently incubated 
with primary antibodies (Table 3). After the chromogenic 
visualization step using the ultraView Universal DAB 
Detection Kit (Ventana Medical Systems, Inc.) or EnVision 
FLEX /HRP (Dako, Agilent Technologies, Inc.), slides 
were counterstained with hematoxylin and coverslipped. 
Appropriate positive and negative controls were stained 
concurrently to validate the staining procedure.
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